Results 61 to 70 of about 18,680 (257)

Who can safely discontinue lifelong follow‐up among patients with sporadic pheochromocytoma and paraganglioma?

Journal of Internal Medicine, EarlyView.
Background Current guidelines recommend at least 10 years of follow‐up for all pheochromocytoma and paraganglioma (PPGL) patients and lifelong monitoring for high‐risk individuals. Nonetheless, data identifying patients who may not require routine lifelong follow‐up are scarce.
Min Jeong Park, Seung Shin Park, Won Woong Kim, Su‐Jin Kim, Yu‐Mi Lee, Kyu Eun Lee, Tae‐Yon Sung, Jae‐Kyung Won, Dong Eun Song, Jung‐Min Koh, Sara Talvacchio, Tamara Prodanov, Hussam Alkaissi, Karel Pacak, Seung Hun Lee, Jung Hee Kim   +15 more
wiley   +1 more source

Comparison of MIBG uptake in the major salivary glands between Lewy body disease and progressive supranuclear palsy

Clinical Parkinsonism & Related Disorders
Introduction: Cardiac sympathetic denervation is specific to Lewy body disease (LBD). In Parkinson’s disease (PD), sympathetic denervation in the major salivary glands (parotid glands [PG] and submandibular glands [SMG]) has been demonstrated by 123I ...
Junya Ebina, Sunao Mizumura, Mari Shibukawa, Harumi Morioka, Junpei Nagasawa, Masaru Yanagihashi, Takehisa Hirayama, Nobutomo Ishii, Yukio Kobayashi, Akira Inaba, Satoshi Orimo, Osamu Kano   +11 more
doaj   +1 more source

Imaging of High‐Risk Neuroblastoma: Recommendations From SIOPEN Radiology and Nuclear Medicine Specialty Committees

Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
ABSTRACT Neuroblastoma is the most common extracranial solid tumor in early childhood. Its clinical behavior is highly variable, ranging from spontaneous regression to fatal outcome despite intensive treatment. The International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) Radiology and Nuclear Medicine Specialty Committees ...
Annemieke Littooij, Catia Olianti, Herve Brisse, Pier Luigi Di Paolo, Maria Carmen Garganese, Tejas Kapadia, Jurgen Schaefer, Hugh Wallace, Simon Wan, Bart de Keizer, Irmina Sefic Pasic, Julian Rogasch   +11 more
wiley   +1 more source

First-in-man evaluation of 124I-PGN650: A PET tracer for detecting phosphatidylserine as a biomarker of the solid tumor microenvironment [PDF]

, 2017
Purpose: PGN650 is a F(ab′) 2 antibody fragment that targets phosphatidylserine (PS), a marker normally absent that becomes exposed on tumor cells and tumor vasculature in response to oxidative stress and increases in response to therapy.
Dehdashti, Farrokh, Freimark, Bruce D, Frye, Jennifer, Frye, Sarah, Laforest, Richard, Liu, Yongjian, Luehmann, Hannah, Shan, Joseph S, Siegel, Barry A, Sultan, Deborah   +9 more
core   +2 more sources

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High‐Risk Neuroblastoma: A Multi‐Institutional Retrospective Study

Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman, Madeleine King, Rajen Mody, Sara‐Jane Onyeama, Araz Marachelian, Thomas Cash, Sara M. Federico, Meaghan Granger, Ami V. Desai, Suzanne Shusterman, Jennifer H. Foster, Elizabeth Sokol, Chelsee Greer, Keri Streby, Holly J. Meany, Kieuhoa T. Vo, Margaret E. Macy, Rochelle Bagatell   +17 more
wiley   +1 more source

Clinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors

Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
ABSTRACT Introduction Pediatric relapsed or refractory (R/R) solid tumors carry a dismal prognosis, and postrelapse patient experiences are not well described. We present postrelapse outcomes, including number of R/R events and subsequent therapy regimens.
Matthew T. McEvoy, Elizabeth L. Seashore, W. Susan Cheng, Shondra Clay, Jessica A. Casas, Jennifer H. Foster   +5 more
wiley   +1 more source

Uptake index of 123I-metaiodobenzylguanidine myocardial scintigraphy for diagnosing Lewy body disease [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology, 2017
Objective(s): Iodine-123 metaiodobenzylguanidine (123I-MIBG) myocardial scintigraphy has been used to evaluate cardiac sympathetic denervation in Lewy body disease (LBD), including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB).
Yoshito Kamiya, Satoru Ota, Shintaro Okumiya, Kosuke Yamashita, Akihiro Takaki, Shigeki Ito   +5 more
doaj   +1 more source

[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas [PDF]

, 2001
Selecting the appropriate approach for resection and follow-up of pheochromocytomas (PCCs) is highly dependent upon reliable localization and exclusion of multifocal, bilateral, or metastatic disease ...
Bonjer, H.J. (Jaap), Boomsma, F. (Frans), Bosman, F.T.B. (Fré), Bruining, H.A. (Hajo), Harst, E. (Erwin) van der, Herder, W.W. (Wouter) de, Krenning, E.P. (Eric), Krijger, R.R. (Ronald) de, Kwekkeboom, D.J. (Dirk Jan), Lamberts, S.W.J. (Steven), Meiracker, A.H. (Anton) van den, Stijnen, Th. (Theo)   +11 more
core   +3 more sources

[Pheocromocytoma with negative MIBG].

Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 2010
Pheochomocytomas are catecholamine-releasing tumors derived from chromaffin cells. These kind of tumors occur in less than 1% of the patients evaluated for hypertension. The authors present a case of pheochomocytoma difficult to localize because MIBG scintigraphy was negative and elaborate a review about that subject.
Angela, Bento, João, Vasconcelos, António, Jara   +2 more
openaire   +2 more sources

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience

Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson, Menna Shamma, Upeka Senanayake, Shaimaa Sahmoud, Kathleen Duffin, Victoria Howard, David King, Ayesha Fathani, Blanche Lumb, Andrei Pobischan, Irum Latif Memon, Monzir Ahmed, Rhian Thomas, Gerard Millen, Yasmeen Alomari, Sucheta Vaidya, Lynley V. Marshall, Sally L. George, Ramya Ramanujachar, Juliet Gray, Paola Angelini   +20 more
wiley   +1 more source